Afuture perspectives in the treatment of psoriasis: News In biological therapies;Perspectivas Futuras no Tratamento da Psoríase: Novidades em Terapêutica Biológica

Acta Medica Portuguesa

Volumn 24, Issue 6, 2011, Pages 997-1004

  Diamantino, Filipa ^a   Ferreira, Ana ^a  

^a HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIPSORIASIS AGENT; BRIAKINUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INTERLEUKIN 12 INHIBITOR; INTERLEUKIN 23 INHIBITOR; SIPILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

DISEASE SEVERITY; HUMAN; PSORIASIS; REVIEW;

BIOLOGICAL AGENTS; BIOLOGICAL THERAPY; FORECASTING; HUMANS; PSORIASIS;

EID: 84861927126     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. GIFFITHS CEM, BARKER JNWN: Psoriasis: pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271
2. NESTLE FO, KAPLAN DH, BARKER J: Psoriasis. N Eng J Med 2009;361:496-509
3. WEGER W: Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160:810-820
4. WARREN RB, GRIFFITHS CEM: The future of biological therapies. Semin Cutan Med Surg 2010;29:63-3
5. TORRES T, VELHO GC, SANCHES M, SELORES M: Psoríase na era dos biológicos. Acta Med Port 2010;23:493-8
6. PINTO GM, FILIPE P: Normas de boa prática para o tratamento da psoríase em placas-em idade não pediátrica com biológicos. Trab Soc Port Dermatol Venereol 2010;68:47-68
7. PATHIRANA D, ORMEROD AD, SAIAG P et al: European S3-Guidelines on the systemic treatment of psoriasis. J Eur Acad Dermatol 2009;23(Suppl.2): 5-70
8. SMITH CH, ANSTEY AV, BARKER JNWN et al: British association of Dermatologist' guidelines for biologic interventions for psoriasis 2009; Br J Dermatol 2009;161:987-1019
9. MORTEL MR, EMER J: Prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol 2010;9:952-963
10. WIPPEL-SLUPETZKY K, STINGL G: Future perspectives in the treatment of psoriasis. Curr Probl Dermatol 2009;38:172-189
11. BOEHNCKE WH, KATSAMBAS A, ORTONNE JP, PUIG L: EADV preceptorship: advances in dermatology. JEADV 2010; 24:2-24
12. BROMLEY SK, BURAK WR, JOHNSON KG et al: The immunological synapse. Annu Rev Immunol 2001;19:375-396
13. MITTAL M, RAYCAUDHURI SP: Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on block. Indian J Dermatol Venereol Leprol 2010;76:602-9
14. KAVANAUGH A, MCINNES I, MEASE P et al: Golimumab, a new human tumor necrosis factor α, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-986
15. KAVANAUGH A, MEASE P, KRUEGER GC et al: on behalf of the GO-REVEAL Study Group: Golimumab, a new, human, TNF-alpha antibody, administered subcutaneously every four weeks in psoriatic arthritis patients: 104-week efficacy ans safety results of the randomized, placebo-controlled GO-REVEAL sudy. Ann Rheum Dis 2009;68:136
16. ORTONNE JP, TASSEL C, REICH K: Efficacy of certolizumab pegol, a PEGylated Fab'fragment of an anti-TNF-α monoclonal antibody, in patients previously exposed to biological. Preliminary results of a randomized, placebo-controlled phase II clinical trial in psoriasis. Presented at the 16th Congress of the European Academy of Dermatology and Venerology, Vienna, Austria 16-20 May 2007
17. KIRCIK LH, GONZALEZ ME: How and when to use biologics in psoriasis. J Drugs Dermatol 2010;9:106-117
18. VAN DE KERKHOLF, PCM: Novel biologic therapies in development targeting IL-12/IL-23. JEADV 2010;24:5-9
19. LEONARDI C, KIMBALL AB, PAPP KA et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
20. PAPP KA, LANGLEY RG, LEWOHL M et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
21. KIMBALL AB, GORDON KB, LANGLEY RG et al: Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144: 200-7
22. ClinicalTrials. gov: A study comparing the safety and efficay of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis. Disponível em: http://www.clinicaltrials.gov/ct2/show/NCT00570986?term=abt-874&rank=1 [Acedido 10 de Dezembro de 2010]
23. ZABA LC, SUÁREZ-FARIÑAS M, FUENTES-DUCULAN J et al: Effective treatment of psoriasis with etanercept is linked to suppression of Il-17 signaling, not "immediate-response" TNF genes. J Allergy Clin Immunol 2009;124:1022-10
24. HUEBER W, PATEL DD, DRYJA T et al: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52-72
25. WOLK K, WITTE E, WARSZAWSKA K et al: The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009;39:3570-81
26. Phase 2 study of tasocitinib for the treatment of plaque psoriasis. Disponível em: http://www.empr.com/phase-2-study-of-tasocitinib-for-the-treatment-of-plaque-psoriasis/article/180576/; [Acedido 10 de Dezembro de 2010]
27. BOY MG, WANG C, WILKINSON BE et al: Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690550 in patients with psoriasis. J Invest Dermatol 2009;129:2299-302
28. LANGLEY R, PAPP K, BISSONNETTE R et al: Safety profile of intravenous and subcutaneous siplizumab, an anti-Cd2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol 2010;49:818-828
29. VIEIRA FJF, CALLADO MRM, VIEIRA WP: Abatacept as na option therapy in difficult to treat psoriatic arthritis. Rheumatol Int 2010;30:849-850
30. MEASE P, GENOVESE MC, GLADSTEIN G, et al: Abatacept in the treatment of patients with psoriatic arthritis: results of a double-blind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum 2010 (abs)